Irritable Bowel Syndrome (IBS)

Editor's Choice

Inflammatory Bowel Disease Tied to Thromboembolism Risk

Patients suffering from inflammatory bowel disease have twice the risk of developing venous thromboembolism compared to the general population, according to a study published online Feb. 21 in Gut.

LATEST ARTICLES

Linaclotide: A guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation

Constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation affect millions of Americans. Use of agents currently available for treatment is not supported by well-controlled clinical studies. A new drug application for linaclotide, an orally administered guanylate cyclase type-C receptor agonist for treatment of IBS-C and chronic constipation, was submitted to the US Food and Drug Administration (FDA) with a target action date of June 2012.

New Tool: Rx Adherence Predictor

Now you can determine in advance the likelihood of a patient filling and staying on their medications. This tool can support your ability to prioritize and target patients who may benefit from counseling about the importance of maintaining your prescribed drug regimen.

Probiotics are gaining popularity to treat GI problems as well as to promote good health

This article discusses why probiotics are becoming popular to treat inflammatory bowel disease as well as to stay healthy.

Irritable bowel syndrome gains new treatment

Amitiza has gained a new indication—to treat irritable bowel syndrome with constipation in women.

The pharmacologic management of Crohn's disease

This article discusses pharmacologic options for the treatment of Crohn's disease, including aminosalicylates, corticosteroids, immunosuppresant agents, and biologic agents.